Bristol-Myers Squibb and Sanofi-Aventis won a round in their patent battle with Apotex when a federal judge ordered the Canadian firm to stop selling its generic version of the blockbuster heart drug Plavix. The judge said it appeared unlikely Apotex would prevail when the dispute goes to trial, therefore sales of the generic should be halted to avoid losses to the other two companies.

Full Story:

Related Summaries